Emollient bath additives 'no benefit' in childhood eczema

Emollient bath additives provide no clinical benefit when added to standard eczema care in children, a trial published in the BMJ has shown.

Emollient bath additives provide minimal or no additional benefit beyond standard care in the management of eczema in children. | iStock
Emollient bath additives provide minimal or no additional benefit beyond standard care in the management of eczema in children. | iStock

'Bath additives don't work - basically you're pouring stuff down the plughole,' said Dr Miriam Santer, a GP and associate professor at Southampton University in primary care research, who led the BATHE study.

To determine the clinical and cost effectiveness of emollient bath additives, Dr Santer and colleagues recruited 483 children aged 1—11 years diagnosed with eczema from 96 general practices in England and Wales.

Further information

BMJ study MIMS Dermatology Clinic

Participants were randomly assigned to receive prescriptions for bath additives or not, for 1 year. Both groups continued with standard eczema management, including leave-on emollients.

Eczema control was measured weekly for 16 weeks using the patient-oriented eczema measure (POEM), with scores of 0-7 indicating mild eczema and scores of 8—16 and 17—28 indicating moderate and severe symptoms, respectively.

No significant difference

The researchers found that mean POEM scores over the 16-week period were not significantly difference between the children who had emollient added to their baths and those who did not (7.5 vs 8.4).

After controlling for baseline severity and confounders (such as ethnicity and topical corticosteroid use) and allowing for clustering of participants within centres and responses within participants over time, POEM scores in the no bath additives group were 0.41 points higher than in the bath additives group (95% CI −0.27 to 1.10), below the minimal clinically important difference of 3 points.

There were also no significant differences between the groups for additional measures, including eczema severity over 1 year, the number of eczema flare-ups, quality of life, cost-effectiveness and adverse effects.

Other treatments

Dr Martin Ward Platt, a consultant paediatrician at the Royal Victoria Infirmary in Newcastle, said the trial's findings suggested NHS money should be spent on other treatments.

'That doesn't mean they [bath additives] shouldn't be available on sale for people who want to give them a try or use them out of personal preference, but the notion that one should prescribe them and spend public money on them is heavily undermined,' he said.

'There's a good case now to not have these on prescription and use the money elsewhere.'

Prescribing of bath additives in England costs the NHS more than £23 million annually.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in